IL2RA and neoplasm: The influence of CD25 within the tumor microenvironment has also been extensively investigated, emphasizing the potential of mitigating Treg-mediated immune suppression as a pivotal facet of tumor immunotherapy, positioning CD25 as a viable target for immunotherapeutic strategies (17–19).